BioMarin Pharma (BMRN) Announces 7.5M Share Common Stock Offering

August 8, 2016 4:33 PM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced an offering, subject to market and other conditions, of 7,500,000 shares of its common stock in an underwritten public offering. BioMarin has also granted the underwriters a 30-day option to purchase an additional 750,000 shares of common stock. BioMarin intends to use the net proceeds from the offering for general corporate purposes, including clinical trials of its product candidates and the expansion of its manufacturing capacity, particularly with respect to its manufacturing capability for its gene therapy program.

Goldman, Sachs & Co. and BofA Merrill Lynch are acting as joint book-running managers for the offering.

The offering of the shares described above has been registered under the Securities Act of 1933, as amended. For additional information relating to the offering, BioMarin refers you to its Registration Statement on Form S-3, which BioMarin filed with the Securities and Exchange Commission (the “SEC”) on August 8, 2016 and which became immediately effective on the same date. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, by phone at (866) 471-2526 or by email at; and BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email at

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Equity Offerings

Related Entities

Merrill Lynch, Bank of America, S3

Add Your Comment